Overexpression of Ras(V12) in MCF10A cells, an immortalized mammary epithelial cell line, leads to transformation of these cells. We demonstrate that this is accompanied by degradation of C/EBPbeta1. C/EBP beta is a transcription factor in which three protein isoforms exist because of alternative translation at three in-frame methionines. When C/EBPbeta1 is expressed in MCF10A-Ras(V12) cells, immunoblot analysis reveals that C/EBPbeta1 is degraded in these cells. Treatment of MCF10A-Ras(V12)-C/EBPbeta1 cells with the cdk inhibitor roscovitine leads to stabilization of C/EBPbeta1. It has been previously shown that cdk2 phosphorylates C/EBPbeta on Thr235. We demonstrate that mutation of Thr235 to alanine in C/EBPbeta1 is sufficient to restore the stability of C/EBPbeta1 expression in MCF10A-Ras(V12) cells. Overexpression of Ras(V12) in primary cells induces senescence rather than transformation, thus suppressing tumorigenesis. C/EBPbeta is required for Ras(V12)-induced senescence in primary mouse embryonic fibroblasts. Upregulation of interleukin-6 (IL6) by C/EBPbeta has been shown to be necessary for oncogeneinduced senescence, but the specific isoform of C/EBPbeta has not been investigated. We show that the C/EBPbeta1 isoform upregulates IL6 when introduced into normal fibroblasts. In addition, we show that C/EBPbeta1 induces senescence. Taken together, degradation of C/EBPbeta1 by Ras activation may represent a mechanism to bypass OIS.
Introduction
Ras signaling leads to proliferation and cell survival and is activated in many cancers. Aberrant function of the Ras pathway is very common in breast cancers (reviewed in Malaney and Daly, 2001; Dunn et al., 2005) . Introduction of activated Ras(V12) into most immortalized cell lines, including the immortalized MCF10A human mammary epithelial cell (MEC) line, leads to transformation. However, when Ras(V12) is expressed in primary cells, these cells senesce instead of undergoing transformation. This oncogene-induced senescence (OIS) displayed by primary cells represents a tumor suppressive mechanism inherent in these cells.
Research is ongoing to determine the proteins and pathways involved in Ras transformation and Rasinduced senescence. It is important to determine the different molecular factors necessary for Ras transformation versus Ras-induced senescence, as these could be critical targets for cancer therapy. C/EBPbeta, an essential downstream mediator of both Ras transformation (Zhu et al., 2002) and activated Ras/Raf (a downstream mediator of Ras signaling)-induced senescence (Sebastian et al., 2005; Kuilman et al., 2008) , is a member of the CCAAT/ enhancer binding protein (C/EBP) family of basic leucine-zipper transcription factors. Three protein isoforms of C/EBPbeta exist because of alternative translation initiation at three in-frame methionines. In humans, full-length C/EBPbeta1 begins at the first inframe ATG and has an apparent molecular weight of 52 kDa. C/EBPbeta2 begins at the second in-frame methionine, 23 amino acids downstream from the first, and appears as a doublet on immunoblots at 45 and 48 kDa. C/EBPbeta3 begins at the last in-frame ATG at amino acid 198 and has an apparent molecular weight of 20 kDa. C/EBPbeta1 and C/EBPbeta2 both contain the C-terminal DNA binding/dimerization domain and an N-terminal transactivation domain, allowing them to function as transcriptional activators. C/EBPbeta3 lacks the N-terminal transactivation domain and thus represses transcription (Descombes and Schibler, 1991) .
The C/EBPbeta knockout mouse demonstrated that C/EBPbeta is essential for proper development of the mammary gland. These mice display a dual phenotype: a defect in MEC proliferation and differentiation (Robinson et al., 1998; Seagroves et al., 1998) . The production of multiple isoforms of C/EBPbeta may explain how a single transcription factor can regulate both differentiation and proliferation. The functional differences between the transactivator isoforms of C/EBPbeta have not been studied in great detail. C/EBPbeta1 is often mistaken for the 48 kDa (top band) of the C/EBPbeta2 doublet on immunoblots largely because C/EBPbeta1 is not expressed in trans-formed cell lines (see below). Because of this difficulty in deciphering between C/EBPbeta1 and -2, and because both isoforms are transcriptional activators, many consider them to be functionally redundant. However, recent studies indicate that C/EBPbeta1 and -2 both have unique and important roles. For example, C/EBPbeta1, but not C/EBPbeta2, cooperates with c-Myb to transactivate differentiation genes in myeloid cells by the ability of C/EBPbeta1, but not C/EBPbeta2, to recruit the SWI/SNF chromatin remodeling complex (Kowenz-Leutz and Leutz, 1999) . In addition, C/EBPbeta1, but not C/EBPbeta2, can be modified by the post-translational modification SUMO-2/3 (Eaton and Sealy, 2003) . Furthermore, a striking difference exists in the expression profiles of C/EBPbeta1 and -2 in normal versus tumorigenic human mammary epithelial cells (Eaton et al., 2001; Koslowski et al., 2009) . C/EBPbeta1 is found in normal MECs from reduction mammoplasties, whereas C/EBPbeta2 is not. Moreover, a majority of human breast tumors express significant levels of C/EBPbeta2. (Eaton et al., 2001) . C/EBPbeta2 is expressed in breast cancer cell lines, whereas p52-C/ EBPbeta1 is not. Further investigation indicated that these distinct expression profiles have functional significance. C/EBPbeta2, but not C/EBPbeta1, can transactivate cyclin D1 (Eaton et al., 2001) and PLAC1 (Koslowski et al., 2009) , two genes the protein products of which are involved in proliferation and commonly upregulated in breast cancer. Furthermore, C/EBPbe-ta2, but not C/EBPbeta1, overexpression in MCF10A MECs transforms this cell line (Bundy and Sealy, 2003) . Taken together, these data suggest that C/EBPbeta1 and -2 are functionally distinct in MECs, with C/EBPbeta1 having a role in non-proliferating MECs, and C/ EBPbeta2 promoting proliferation and other transforming characteristics.
As C/EBPbeta is an essential downstream mediator of Ras signaling, the production of multiple isoforms of C/EBPbeta may be a potential mechanism to explain the functional differences observed upon expression of Ras(V12). C/EBPbeta is crucial for both Ras transformation and Ras-induced senescence. Zhu et al. (2002) reported that v-Ha-ras transgenic mice deficient for C/EBPbeta had smaller and fewer skin tumors than did v-Ha-ras mice that expressed C/EBPbeta. They also demonstrated that C/EBPbeta cooperates with Ras(V12) in transformation of NIH-3T3 cells. Recently, C/EBPbeta has been shown to be necessary for Rasinduced senescence (Sebastian et al., 2005) . In addition, activation of interleukin-6 (IL6) by C/EBPbeta is essential for activated Raf(E600)-induced senescence (Kuilman et al., 2008) . C/EBPbeta is phosphorylated in response to Ras signaling, and this phosphorylation is often critical for the Ras-induced phenotype observed. A residue in C/EBPbeta that is frequently phosphorylated upon Ras(V12) introduction is threonine 235 (Thr235) in humans (Thr189 in rat, Thr188 in mouse). Shuman et al. (2004) revealed that Ras(V12) expression in NIH-3T3s enhanced phosphorylation of Thr189 in C/EBPbeta by cyclin-dependent kinase-2 (cdk2). In addition, this site in C/EBPbeta2 is necessary for the Ras-stimulated interaction of C/EBPbeta2 and serum response factor for transactivation of serum response element in NIH-3T3 cells, and was shown to be phosphorylated by Erk-2 .
As mentioned earlier, transformed cell lines typically do not express p52-C/EBPbeta1. However, the immortal but non-transformed human mammary epithelial cell line, MCF10A, expresses all three C/EBPbeta isoforms. In this study, we demonstrate that when Ras(V12) is introduced into MCF10As, transformation is accompanied by degradation of p52-C/EBPbeta1. Treatment of MCF10A-Ras cells forced to express C/EBPbeta1 with the cdk inhibitor roscovitine stabilizes p52-C/ EBPbeta1. It has been previously shown that cdk2 phosphorylates C/EBPbeta on Thr235 (Shuman et al., 2004; Li et al., 2007) . We demonstrate that mutation of Thr235 to alanine in C/EBPbeta1 is sufficient to restore stability of p52-C/EBPbeta1 expression in MCF10A-Ras cells. As we observed that Ras(V12) negatively regulates C/EBPbeta1 in immortalized MCF10As, a cell line that escapes senescence upon introduction of Ras(V12), and we know that Ras(V12) induces senescence in a C/EBPbeta-dependent manner in normal cells, we decided to examine whether C/EBPbeta1 was able to induce senescence. Induction of IL6 by C/EBPbeta is critical for activated Raf(E600)-induced senescence (Kuilman et al., 2008) . When C/EBPbeta1 and -2 are compared, only full-length C/EBPbeta1 strongly upregulates IL6 when introduced into normal human diploid fibroblasts (HDFs), WI-38. In addition, we show that C/EBPbeta1 is a more potent inducer of senescence in these cells. Our results indicate that C/EBPbeta1 is negatively regulated by Ras(V12) in immortalized MCF10As and this full-length C/EBPbeta isoform is able to induce senescence in WI-38 cells by inducing IL6. Taken together, degradation of C/EBPbeta1 by Ras activation may represent a mechanism to bypass OIS.
Results

Ras(V12) negatively regulates C/EBPbeta1 by causing degradation of C/EBPbeta1 in MCF10As
Expression of all three isoforms of C/EBPbeta is observed by immunoblot of cell lysates from MCF10As, an immortalized yet untransformed MEC line ( Figure 1a , lane 1). Introduction of Ras(V12) into MCF10As (MCF10A-Ras) transforms this cell line (Supplementary Figure 1 ). An examination of C/EBPbeta expression in MCF10A-Ras cells indicates that there is a striking loss of C/EBPbeta1 expression ( Figure 1a , lane 2).
After observing that introduction of Ras(V12) into MCF10As leads to loss of endogenous C/EBPbeta1 expression, we expressed T7-tagged-C/EBPbeta1 with the retroviral vector LZRS-T7-C/EBPbeta1-IRES-eGFP. Infected cells were sorted by fluorescenceactivated cell sorting using green fluorescent protein (GFP) as a marker. Immediately after sorting, p52-T7-C/EBPbeta1 was expressed in both MCF10A and To determine whether T7-C/EBPbeta1 is being proteolyzed by the proteasome in MCF10A-Ras cells, we treated the cells with MG132, a proteasomal . Equal amounts of total protein were loaded into each lane of a 12% SDS-PAGE. The different isoforms of C/EBPbeta are indicated with arrows. Note-expression levels of the isoforms of C/EBPbeta in MCF10A cells can be somewhat variable depending on passage. Bars indicate the mobilities of standard molecular weight markers, expressed in kDa, in all figures. Immunoblotting was performed with a C-terminal C/EBPbeta antibody (Santa Cruz C-19) at a dilution of 1:5000. The molecular weight markers used in this figure are the same as those used in previous papers, which identify C/EBPbeta1 as a 55 kDa protein. The remaining figures in this paper use a different molecular weight marker that shows C/EBPbeta1 having an apparent molecular weight of 52 kDa. (b) MCF10A and MCF10A-Ras cells infected with LZRS-T7-C/EBPbeta1-IRES-eGFP and sorted by FACS for GFP-positive cells. C/EBPbeta1 is the only C/EBPbeta isoform produced by this retrovirus because the second ATG necessary to translate C/EBPbeta2 has been mutated along with a small open reading frame (ORF) required for translation of C/EBPbeta3 (Calkhoven et al., 2000) . The samples shown on this immunoblot were prepared three weeks after sorting. Equal amounts of total protein were loaded into each lane of a 10% SDS-PAGE. Immunoblot analysis of lanes 1 and 2 was performed with a T7tagged mouse monoclonal antibody (Novagen, Gibbstown, NJ, USA) at 1:10 000, whereas lanes 3 and 4 are with an anti-C/EBPbeta C-terminal antibody (Santa Cruz C-19) at a dilution of 1:5000. Arrows indicate full-length p52-T7-C/EBPbeta1, along with smaller degradation products of T7-C/EBPbeta1. (c) MCF10A (lanes 1-7) and MCF10A-Ras (lanes 8-14) cells infected with LZRS-T7-C/ EBPbeta1-IRES-eGFP and sorted by FACS for GFP-positive cells. Cell lysates were prepared every 4 days for 24 days. Equal amounts of total protein were loaded into each lane of a 10% SDS-PAGE. Immunoblot analysis was performed with the T7-tagged antibody (Novagen) at a dilution of 1:10 000. Arrows indicate full-length p52-T7-C/EBPbeta. Immunoblot analysis with the b-tubulin antibody is shown as a loading control (Sigma T7816 at 1:10 000) (beta ¼ C/EBPbeta, 10A ¼ MCF10A).
C/EBPbeta1 and senescence AA Atwood and L Sealy inhibitor. Treatment of MCF10A-Ras-C/EBPbeta1 cells with MG132 stabilized the expression of p52-T7-CEBPbeta1 (Figure 2a ). A similar effect was observed on treatment with lactacystin, another proteasomal inhibitor (data not shown). Furthermore, treatment of MCF10A-Ras cells with MG132 stabilizes endogenous C/EBPbeta1 (Figure 2b ). We then wanted to determine whether degradation of C/EBPbeta1 might be ubiquitin mediated. MCF10A-Ras-C/EBPbeta1 cells were treated with MG132 and immunoprecipitated with T7-tagged antibody beads. Immunoblot analysis with a ubiquitin antibody demonstrated that MCF10A-Ras-C/EBPbeta1 cells treated with MG132 exhibit increased reactivity with this antibody compared with controls ( Figure 2d , lane 5 versus lanes 3 and 4). Immunoblot analysis of the treated cells with the C/EBPbeta antibody demonstrates a ladder of higher molecular weight bands that coincide with the molecular weights of bands in the ubiquitin immunoblot (Figure 2d , lanes 2 and 5, see arrows), indicating ubiquitination of C/EBPbeta1.
Most breast cancer cell lines exhibit activation of the Ras pathway through activation of upstream receptors, upregulation of Ras itself or through activation of downstream signaling molecules (Malaney and Daly, 2001; Dunn et al., 2005, Supplementary Figure 1 ). Therefore, we expressed T7-C/EBPbeta1 in breast cancer cell lines MDA231 and MDA435, in which the Ras pathway is activated. Expression of T7-C/EBPbeta1 in MDA231s and MDA435s decreases over time, similar to MCF10A-Ras-C/EBPbeta1 cells, and p52-T7-C/ EBPbeta1 was stabilized when MDA231-C/EBPbeta1 and MDA435-C/EBPbeta1 cells were exposed to MG132 (Figure 2c , lane 3 versus 4, data not shown). were loaded into each lane of a 10% SDS-PAGE. Immunoblot analysis was performed with a T7-tagged mouse monoclonal antibody (Novagen) at 1:10 000. The arrow indicates p52-T7-C/EBPbeta1. b-tubulin was used as the loading control for all of the above immunoblots (Sigma T7816). (d) MCF10A-Ras cells infected with LZRS-T7-C/EBPbeta1-IRES-eGFP and sorted by FACS for GFPpositive cells. Lane 3 consists of uninfected MCF10A-Ras cells. Cells were untreated (lanes 1, 3 and 4) or treated with 50 mM MG132 for 8 h and with 5 mM N-ethylmaleimide for 30 min (lanes 2 and 5). Lanes 1 and 2 consist of cell lysates, whereas lanes 3-5 consist of immunoprecipitations with T7-tagged antibody beads (Novagen). Immunoprecipitations were performed as described previously (Eaton and Sealy, 2003) with the following exceptions: the immunoprecipitations were for 15 min, and 50 mM MG132 and 5 mM N-ethylmaleimide were included in the immunoprecipitation buffer. Immunoblot analysis was performed with the Santa Cruz C-19 C-terminal C/EBPbeta antibody (lanes 1 and 2) or ubiquitin antibody (FK2 Enzo Life Sciences, Plymouth Meeting, PA, USA)
C/EBPbeta1 and senescence AA Atwood and L Sealy Treatment with the cdk inhibitor roscovitine or mutation of C/EBPbeta1 Thr235 to alanine stabilizes expression of T7-C/EBPbeta1 in MCF10A-Ras cells Ras(V12) expression in MCF10A-Ras cells may lead to phosphorylation of C/EBPbeta1, which subsequently causes degradation of C/EBPbeta1. To further investigate the mechanism by which Ras negatively regulates C/EBPbeta1, MCF10A-Ras-C/EBPbeta1 cells were treated with a panel of kinase inhibitors that inhibit kinases known to phosphorylate C/EBPbeta. Treatment with the cdk inhibitor roscovitine stabilized expression of p52-T7-C/EBPbeta1 (Figure 3a , compare lanes 2 and 4). C/EBPbeta is phosphorylated on Thr235 by cdk2 (Shuman et al., 2004; Li et al., 2007) . More specifically, C/EBPbeta1 can be phosphorylated on Thr235 by cdk2 in vitro (Figure 3c ). This phosphorylation can be inhibited by treatment with roscovitine (Shuman et al., 2004; Li et al., 2007, data not shown) . Treatment with roscovitine was the only treatment that stabilized expression of p52-T7-C/EBPbeta1 in MCF10A-Ras cells. Treatment of MDA231-C/EBPbeta1 cells with roscovitine also stabilized the expression of p52-T7-C/ EBPbeta1 (data not shown). Importantly, cdk2 is activated in MCF10A-Ras and MDA231 cells (Supplementary Figure 1c ).
To confirm that phosphorylation by cdk2 on C/EBPbeta1-Thr235 was leading to a degradation of C/EBPbeta1, Thr235 was mutated to alanine (T235A); hence, this residue could no longer be phosphorylated. An LZRS-T7-C/EBPbeta1T235A-IRES-eGFP retroviral vector was constructed, and the resulting retrovirus was used to infect MCF10A-Ras cells. These cells were sorted by FACS using GFP as a marker. Mutation of Thr235 to alanine in C/EBPbeta1, thus preventing phosphorylation of this residue by cdk2, stabilized the expression of p52-T7-C/EBPbeta1 after 3 weeks in culture ( Figure 3b , lane 3 versus 6) as compared with T7-C/EBPbeta1 that did not contain this mutation (Figure 3b , lane 2 versus 5). T7-C/EBPbeta1 and T7-C/ EBPbeta1T235A expression did not have an effect on the transformed phenotype of MCF10A-Ras cells, as the ability of these cells to form colonies in soft agar was unaltered ( Supplementary Figure 2) . T7-C/EBPbeta1 and T7-C/EBPbeta1T235A are unable to induce senescence in MCF10A cells, in part because these cells have the p14ARF/p15INK4B/p16INK4A locus deleted (Iavarone and Massague, 1997) . p16INK4A is an important factor in OIS, and C/EBPbeta-induced senescence signals through this tumor suppressor during OIS (Sebastian et al., 2005) . In addition, C/EBPbeta has been shown to induce p15INK4B during OIS (Kuilman et al., 2008) .
C/EBPbeta1 is not degraded upon Ras(V12) introduction into WI-38 normal HDFs Recently, C/EBPbeta has been shown to be essential for Ras(V12)-and Raf(E600)-induced senescence in mouse embryonic fibroblasts and HDFs, respectively (Sebastian et al., 2005; Kuilman et al., 2008) . We decided to determine which isoform of C/EBPbeta is responsible for induction of senescence. We hypothesized that as Ras negatively regulates C/EBPbeta1 by leading to its degradation during Ras transformation, this full-length isoform of C/EBPbeta is responsible for inducing senescence. First, we wanted to determine whether introduction of Ras(V12), and thus induction of senescence, negatively regulates C/EBPbeta1 expression in normal HDFs, cells commonly used to study senescence. Figure 4a is an immunoblot with an antibody specific for the N-terminal 23 amino acids present only in C/EBPbeta1. This immunoblot demonstrates that Ras(V12) does not lead to degradation of C/EBPbeta1 in normal WI-38 cells (Figure 4a, lanes 2 and 3) .
C/EBPbeta1 expression in WI-38 cells inhibits growth
Next, we tested whether exogenous expression of C/EBPbeta1 had an effect on growth of normal fibroblasts. We performed a colony formation assay using uninfected WI-38 cells or WI-38 cells infected with LZRS-T7-C/EBPbeta1-IRES-eGFP or LZRS-eGFP and sorted by FACS using GFP as a marker. As shown in Figures 4b and c , there were significantly fewer WI-38-T7-C/EBPbeta1 colonies compared with controls (P ¼ 0.007), indicating that T7-C/EBPbeta1 expression in WI-38 cells inhibits growth and potentially causes these cells to senesce.
To confirm these findings, we performed a bromodeoxyuridine assay using uninfected WI-38 cells, or sorted WI-38 cells expressing T7-C/EBPbeta1 and GFP or GFP only, as shown in Figures 4d and e . WI-38-T7-C/EBPbeta1 cells have significantly less bromodeoxyuridine staining than do controls (P ¼ 0.027), confirming the results from Figure 4b that C/EBPbeta1 expression in WI-38 cells inhibits their proliferation.
C/EBPbeta1 induces IL6 in WI-38 fibroblasts Kuilman et al. (2008) reported that activated Raf(E600)induced senescence in HDFs is due to activation of an inflammatory transcriptome. This study demonstrated that activated Raf(E600)-induced senescence was dependent on IL6 activation by C/EBPbeta. Thus, we examined whether a specific transactivator isoform of C/EBPbeta was inducing IL6 expression. RNA was prepared 6 days after infection from WI-38 cells infected with LZRS-T7-C/EBPbeta1-IRES-eGFP, LZRS-T7-C/ EBPbeta2-IRES-eGFP, LZRS-GFP or pBABE-Ras(V12)-puromycin. cDNA was prepared from the RNA and qPCR was performed using an IL6 primer. T7-C/EBPbeta1-WI-38 cells and the positive control Ras(V12)-expressing cells highly upregulate IL6 RNA 6.6-fold and eightfold, respectively (Figure 5a ). T7-C/ EBPbeta2 only induces IL6 expression 2.1-fold compared with uninfected cells, despite approximately equal levels of T7-C/EBPbeta1 and T7-C/EBPbeta2 protein being expressed on day 6 ( Figure 5b) . C/EBPbeta1, and to a lesser extent C/EBPbeta2, induces senescence in WI-38 HDFs Knowing that C/EBPbeta1 induces IL6 to a much greater level than does C/EBPbeta2, we determined whether C/EBPbeta1 could cause senescence more effectively. WI-38 cells infected with LZRS-T7-C/ EBPbeta1-IRES-eGFP, LZRS-T7-C/EBPbeta2-IRES-eGFP, LZRS-GFP or pBABE-Ras(V12)-puromycin were fixed and stained for senescence-associated b-galactosidase 6 days after infection (Figure 6a ). On an average, over 53% of T7-C/EBPbeta1-WI-38 cells and over 55% of positive control Ras(V12)-WI-38 cells stained a bright blue, compared with 34.5% of T7-C/ EBPbeta2-expressing cells. Less than 20% of control consist of uninfected MCF10A-Ras cells, lanes 2 and 5 of MCF10A-Ras-C/EBPbeta1 cells immediately after sorting and 3 weeks after sorting, respectively, and lanes 3 and 6 of MCF10A-Ras-C/EBPbeta1T235A cells immediately after sorting and 3 weeks after sorting, respectively. Equal amounts of total cell protein were loaded and analyzed by means of 10% SDS-PAGE. Immunoblotting was performed with an anti-T7-tagged mouse monoclonal antibody (Novagen) at 1:10 000. The arrow indicates p52-T7-C/EBPbeta1. Immunoblot analysis for GAPDH (Santa Cruz) was performed as a loading control. (c) Purified rat C/EBPbeta1 (Lap1, which is smaller than human C/EBPbeta1) was in vitro phosphorylated with purified, active cdk2/cyclin A2 (Signalchem, Richmond, BC, Canada). Equal amounts of C/EBPbeta1 alone (lane 1) or in vitro phosphorylated C/EBPbeta1 (lane 2) were run on 10% SDS-PAGE.
Immunoblotting was performed with an antiphosphoThr235 C/EBPbeta antibody (Cell Signaling Technology, Beverly, MA, USA) at 1:2000 or with antiT7 antibody (Novagen) at 1:10 000 dilution (10A ¼ MCF10A, beta ¼ C/EBPbeta).
uninfected or LZRS-GFP cells stained a faint blue. A statistically significant difference in blue staining exists between T7-C/EBPbeta1-and Ras(V12)-expressing WI-38 cells versus uninfected cells, resulting in P-values of 0.005 and 0.003, respectively (Figure 6b ). This is consistent with T7-C/EBPbeta1-expressing cells inhibiting Immunoblot analysis was performed with an antibody specific to C/EBPbeta1 as described in Eaton et al. (2001) . The arrow indicates endogenous p52-C/EBPbeta1. Immunoblot analysis for b-tubulin was performed as a loading control (Sigma T7816)
WI-38 human diploid fibroblasts were infected with LZRS-GFP or LZRS-T7-C/EBPbeta1-IRES-eGFP and sorted by FACS using GFP as a marker. In total, 800 cells were plated and after 10 days the cells were fixed with 95% ethanol and stained with Gills hematoxylin (Sigma). The number of stained colonies was counted. T7-C/EBPbeta1 expression was verified by immunoblot (data not shown). (c) Quantitative comparison of the colony formation assay. This experiment was repeated three times with the s.d. represented by error bars. Quantitative comparison using the Student's t-test indicates that there is a statistically significant difference in colony number in T7-C/EBPbeta1-expressing WI-38 cells versus uninfected or GFP only. *P ¼ 0.007. (d) WI-38 human diploid fibroblasts were infected with LZRS-GFP or LZRS-T7-C/EBPbeta1-IRES-eGFP and sorted by FACS using GFP as a marker. A total of 13 000 cells were seeded per well in an 8-well chamber slide 6 days after infection. At 24 h after plating, the cells were pulsed with 10 mg/ml Brdu (Sigma) for 24 h. Cells were then fixed in formalin for 5 min. The Invitrogen streptavidin-biotin system for the Brdu staining kit was then followed as per the manufacturer's instructions. The dark nuclear stain indicates replicating cells in which Brdu was incorporated (examples indicated by arrows). Hematoxylin was used as the counterstain. T7-C/EBPbeta1 expression was verified by immunoblotting (data not shown). (e) Quantitative comparison of the Brdu assay. Quantitative comparison using the Student's t-test indicates that there is a statistically significant difference in Brdu staining in T7-C/EBPbeta1-expressing WI-38 cells versus uninfected or GFP only. *P ¼ 0.027. s.d. is represented by error bars.
C/EBPbeta1 and senescence AA Atwood and L Sealy growth as shown earlier. Although T7-C/EBPbeta2 cells induced senescence to a lesser extent than did T7-C/EBPbeta1, the percentage of blue cells was still statistically significant as compared with uninfected cells, with a P-value of 0.03. Approximately equal levels of T7-C/EBPbeta1 and T7-C/EBPbeta2 were expressed (Figure 5b ). To confirm these findings, p16INK4A protein levels were examined, as p16INK4A is upregulated during senescence. WI-38 cells were uninfected, infected with LZRS-T7-C/EBPbeta1-IRES-eGFP, LZRS-T7-C/EBP-beta2-IRES-eGFP or LZRS-GFP, cell lysates were prepared 6 days after infection and immunoblot analysis was performed for p16INK4A expression. Figure 6c indicates that C/EBPbeta1 and C/EBPbeta2 expression in WI-38 cells induces p16INK4A expression, verifying the induction of senescence.
Discussion
Introduction of Ras(V12) into immortalized MCF10As transforms these cells. We demonstrate in this study that Ras(V12) introduction into MCF10As and its subsequent transformation is accompanied by degradation of C/EBPbeta1. We show that when T7-C/EBPbeta1 is expressed in MCF10A and MCF10A-Ras cells, MCF10A-C/EBPbeta1 cells maintain expression of p52-T7-C/EBPbeta1, whereas MCF10A-Ras cells degrade p52-T7-C/EBPbeta1. Stability of C/EBPbeta1 expression may be regulated by ubiquitin-dependent degradation (Figure 2d ). It has been previously demonstrated that p52-C/EBPbeta1 is expressed in normal mammary epithelial tissue and cultured normal MECs, but not in breast cancer cells (Eaton et al., 2001) . The Ras pathway is activated in most breast cancers. Immunoblot analysis was performed with an anti-C/EBPbeta C-terminal antibody (Santa Cruz C-19) at 1:5000. Arrows indicate the particular isoforms of C/EBPbeta. T7-beta indicates the exogenously expressed protein. C/EBPbeta2 is smaller than the endogenous one because the T7-tagged rat protein is being expressed, which is smaller than human. Immunoblot analysis for b-tubulin was performed as a loading control (Sigma T7816) (beta ¼ C/EBPbeta).
Induction of IL6 by Real time PCR
C/EBPbeta1 and senescence AA Atwood and L Sealy Expression of T7-C/EBPbeta1 in breast cancer cell lines MDA231 and MDA435 decreased over time, similar to T7-C/EBPbeta1 expression in MCF10A-Ras cells. In addition, treatment of MDA231-and MDA435-C/ EBPbeta1 cells with a proteasomal inhibitor stabilized the expression of p52-T7-C/EBPbeta1. Therefore, it is likely that C/EBPbeta1 is negatively regulated in breast cancer through activation of the Ras pathway.
C/EBPbeta is phosphorylated by a number of kinases in the Ras pathway. Therefore, we treated MCF10A-Ras-C/EBPbeta1 cells with a panel of kinase inhibitors to determine whether inhibiting phosphorylation could stabilize p52-C/EBPbeta1 expression. We found that treatment with the cdk inhibitor roscovitine stabilized C/EBPbeta1 expression. Ras activation activates cdk2 ( Supplementary Figure 1 ; reviewed in Musgrove, 2006) . Six days after infection, 60% confluent cells were fixed in 60 mm plates and stained with the senescence-associated beta-galactosidase kit as per the manufacturer's instructions (Cell Signaling Technology). Five fields per plate were imaged with a light microscope with representative photomicrographs displayed. (b) Quantitative comparison of senescence-associated b-galactosidase stain. This experiment was repeated three times, with s.d. represented by error bars. Quantitative comparison using the Student's t-test indicates that there is a statistically significant difference in blue staining between Ras(V12)-, T7-C/EBPbeta1-and T7-C/EBPbeta2-expressing WI-38 cells and uninfected cells. **Po0.006, *Po0.03. (c) WI-38 cells were infected with LZRS-GFP, LZRS-T7-C/EBPbeta1-IRES-eGFP or LZRS-T7-C/EBPbeta2-IRES-eGFP. Six days after infection, cell lysates were prepared and run on a 10% SDS-PAGE. Equal amounts of protein were loaded into each lane. Immunoblot analysis was carried out with an anti-p16INK4A antibody (Santa Cruz). Immunoblot analysis for b-tubulin was performed as a loading control (Sigma T7816).
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Two independent groups have demonstrated that C/EBPbeta can be phosphorylated on Thr235 by cdk2 (Shuman et al., 2004; Li et al., 2007) . This phosphorylation is specific to the cdk family member cdk2, and when cells are treated with roscovitine, there is a decrease in phosphorylation of Thr235. In addition, knockdown of cdk2 decreases phosphorylation of C/EBPbetaThr235 (Li et al., 2007) . The non-phosphorylatable C/EBPbe-ta1T235A could be stably expressed in MCF10A-Ras cells as compared with wild-type C/EBPbeta1. Therefore, activation of the Ras pathway in MECs negatively regulates C/EBPbeta1 by promoting phosphorylation of C/EBPbeta1 on Thr235 by cdk2 and subsequently leading to degradation of C/EBPbeta1. Loss of T7-C/ EBPbeta1 does take several days. This may be because of an initial compensatory mechanism by the cell leading to increased synthesis of C/EBPbeta1 and/or a requirement for expression of a specific ubiquitin E3 ligase necessary for the degradation of C/EBPbeta1. Although introduction of Ras(V12) into many immortalized cell lines leads to transformation, introduction of Ras(V12) into primary cells has a different effect. Normal fibroblasts, such as WI-38 HDFs, undergo senescence when forced to express oncogenes such as activated Ras(V12) or Raf(E600). Sebastian et al. (2005) demonstrated that C/EBPbeta is necessary for Ras(V12)-induced senescence in mouse embryonic fibroblasts, which occurred in a pRB-dependent manner. Recently, Kuilman et al. (2008) has shown that C/EBPbeta is required for activated Raf(E600)-induced senescence in HDFs. In this study, we set out to determine which transactivator isoform of C/EBPbeta is responsible for OIS, as there is increasing evidence for functional differences between the transactivator isoforms (Kowenz-Leutz and Leutz, 1999; Eaton et al., 2001; Eaton and Sealy, 2003; Bundy et al., 2005) . First, we demonstrate that C/EBPbeta1 is not degraded in senescing WI-38-Ras cells (Figure 4a ). This is because cdk2 is not activated in these cells because of the activation of cdk inhibitors. Kuilman et al. (2008) demonstrated that C/EBPbeta induced senescence through induction of IL6. We show that it is the fulllength isoform, C/EBPbeta1, that is able to robustly induce IL6 expression. Accordingly, we demonstrate that C/EBPbeta1 is the strongest inducer of senescence in WI-38 fibroblasts. C/EBPbeta2 can induce senescence to a lesser extent. It is interesting that C/EBPbeta2 expression in WI-38 fibroblasts does induce senescence. As C/EBPbeta1 is expressed in WI-38 cells, we cannot rule out the possibility that C/EBPbeta2 heterodimerizes with endogenous C/EBPbeta1 to induce IL6, and thus senescence, although at a lower level. Whether as a heterodimer or homodimer, C/EBPbeta2 may be upregulating the expression of other factors involved in OIS. Taken together, it is likely that Ras(V12)/Raf(E600) is working through C/EBPbeta1 to induce IL6 and lead to senescence in normal cells.
We propose that degradation of C/EBPbeta1 by Ras(V12) may be a mechanism by which cells bypass OIS. Loss of expression of full-length C/EBPbeta1 may be necessary for escape from senescence and a step closer to transformation. Further support of this lies in the expression profile of C/EBPbeta1 in normal versus transformed cells. C/EBPbeta1 is present in normal cells and is not degraded when Ras(V12) is introduced into normal cells and induces senescence (Figure 4a ). In addition, this first isoform of C/EBPbeta is negatively regulated by Ras during Ras(V12) transformation of MCF10As (Figure 1) . p52-C/EBPbeta1 expression is not observed in breast cancer cells in which the Ras pathway is activated. The expression pattern of C/EBPbeta1 in normal versus transformed cells supports our current findings that C/EBPbeta1 has an important role in senescence and is negatively regulated during transformation. It is not surprising that a protein that has a critical role in OIS, a tumor suppressive mechanism, is downregulated during transformation. Moreover, it has been recently shown that cdk2 suppresses cellular senescence, consistent with our findings that inhibiting cdk2 with roscovitine stabilizes expression of C/EBPbe-ta1, a factor involved in senescence (Campaner et al., 2010; Hydbring et al., 2010) . In further support of our findings, Kuilman et al. (2008) used a C/EBPbeta construct in which the start sites for C/EBPbeta2 and -3 were mutated such that only C/EBPbeta1 could be translated. They demonstrated that expression of this construct in HDFs led to cell cycle arrest and induction of IL6, consistent with our results.
The production of multiple isoforms of C/EBPbeta is a possible explanation for which this transcription factor could regulate the functional differences observed on expression of Ras(V12). Our data indicate that C/EBPbeta1 is the isoform responsible for mediating Ras(V12)-induced senescence. In contrast to C/EBP beta1, C/EBPbeta2 expression is not negatively regulated during Ras(V12)-induced transformation of MCF10A cells (Figure 1 ). In addition, overexpression of C/EBPbeta2 in MCF10As leads to the acquisition of tumorigenic characteristics (Bundy and Sealy, 2003) , similar to that of Ras(V12) expression in these cells. Therefore, Ras may be signaling to this second isoform of C/EBPbeta during transformation. Unfortunately, it is not possible to knock down each specific isoform of C/EBPbeta through siRNA technology and determine the role of each isoform, because all three isoforms are translated from a single mRNA molecule. Importantly, one study has examined the specific role of C/EBPbeta2 in activated macrophages by generating a knock-in mouse in which the second in-frame methionine necessary for translation of C/EBPbeta2 was replaced with an alanine (Uematsu et al., 2007) . This abolished expression of C/EBPbeta2 in these mice. The induction of C/EBPbeta target genes, such as IL6, was examined in this study. Activated macrophages in mice unable to express C/EBPbeta2 were still able to induce IL6 expression, consistent with our current findings that C/EBPbeta2 is not the primary isoform responsible for induction of IL6 in HDFs.
C/EBPbeta has many functional roles in the cell, even roles that seem conflicting, such as cell survival, cell death, proliferation, senescence and transformation. This may be explained in part by the presence of the different isoforms of C/EBPbeta and their functional differences. Future studies on C/EBPbeta will need to take into consideration that the different isoforms of this transcription factor are likely to have functionally distinct roles. Degradation of C/EBPbeta1 by Ras(V12) may be a mechanism by which cells bypass OIS. Our study sheds light on how Ras signaling is altered in Ras(V12)-induced senescence versus transformation through the regulation of C/EBPbeta1; however, further investigation of what dictates this transition is necessary to better understand this critical switch. It will be important to determine the details of signaling between Ras and C/EBPbeta in normal cells to elucidate mechanisms by which this critical signaling that induces OIS can be triggered or maintained to suppress tumorigenesis.
Materials and methods
Cell lines
Human mammary epithelial cells MCF10A, MDA231 and MDA435 were maintained as described previously (Eaton et al., 2001; Bundy and Sealy, 2003) . WI-38 cells (a gift from the Dr Hal Moses lab, Vanderbilt University) were maintained in Eagle's minimal essential medium supplemented with 10% fetal bovine serum (HyClone Laboratories Logan, UT, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (Life Technologies, Carlsbad, CA, USA). The phoenix-ampho packaging cell line that was obtained from the ATCC (Manassas, VA, USA) with the permission of GP Nolan (Stanford University, Palo Alto, CA, USA) has been previously described (Grignani et al., 1998) and were maintained as described previously (Bundy and Sealy, 2003) .
Cloning of recombinant retroviral constructs and virus preparation
Generation of LZRS-T7-C/EBPbeta1-IRES-eGFP was as follows: IRES-eGFP-LZRS and T7-C/EBPbeta1-pcDNA3.1-His A were generated as described previously (Bundy and Sealy, 2003; Eaton and Sealy, 2003) . T7-C/EBPbeta1-pcDNA3.1 was digested with EcoRI and NotI and incubated with DNA polymerase I. The resulting T7-C/EBPbeta1 insert was ligated into LZRS-IRES-eGFP, which had been digested with EcoRI and BamHI and incubated with DNA polymerase I. This generated LZRS-T7-C/EBPbeta1-IRES-eGFP. LZRS-T7-C/EBPbeta1T235A-IRES-eGFP was generated as follows: NF-IL6T235A-CMV, a generous gift from Akira's laboratory, and our C/EBPbeta1-pRSET-A construct, described in Eaton et al. (2001) , were digested with MscI and BbsI. The T235A fragment was ligated into C/EBPbeta1-pRSET-A to create C/EBPbeta1T235A-pRSET-A. C/EBPbeta1T235A-pRSET-A was digested with HindIII, incubated with DNA polymerase and digested with BamHI to isolate C/EBPbeta1T235A. pcDNA3.1-His-A was digested with BamHI and EcoRV, and C/EBPbeta1T235A insert was ligated into this to create C/EBPbeta1T235A-pcDNA3.1-His-A. C/EBPbeta1T235A-pcDNA3.1-His-A was digested with HindIII and XbaI and incubated with DNA polymerase to isolate T7-C/EBPbeta1-T235A. LZRS-IRES-eGFP was digested with EcoRI and incubated with DNA polymerase. T7-C/EBPbeta1T235A was ligated into LZRS-IRES-eGFP to create LZRS-T7-C/EBP-beta1T235A-IRES-eGFP. LZRS-T7-C/EBPbeta2-IRES-eGFP was generated in a manner similar to that described in Bundy and Sealy, 2003 . The only difference being that T7-C/ EBPbeta2-IRES-eGFP-LZRS was digested with EcoRI, incubated with DNA polymerase and religated. Recombinant amphotropic retroviral stock generation and retroviral infection were performed as described in Bundy and Sealy, 2003 . The pBABE-Ras(V12)-puromycin retroviral construct was a kind gift from Dr Scott Lowe, Cold Spring Harbor. Cells were infected once and selected with 1 mg/ml puromycin (Sigma Chemical, St Louis, MO, USA).
Preparation of cell lysates and immunoblot analysis
Cell lysates were prepared from 100 mm dishes of 90% confluent cells as described previously (Eaton et al., 2001) . Relative protein concentrations were determined using the Protein Assay Reagent (Bio-Rad Laboratories, Hercules, CA, USA) as per the manufacturer's instructions. Proteins were transferred from the gel to Immobilon P filters. Immunoblots were processed as previously described (Bundy and Sealy, 2003) . Anti-pErk, anti-Erk, anti-cdk2 (all Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-pcdk2 (Cell Signaling Technology, Beverly, MA, USA) antibodies were used at a dilution of 1:2000.
Soft agar colony formation assay
Complete media and 2% agar (Difco, Sparks, MD, USA) were mixed in a ratio of 2:1 to produce a 0.7% agar solution. This mixture was pipetted into 60 mm dishes to form the bottom layer. In total, 5 ml of medium containing 1 Â 10 5 cells was mixed with 2.5 ml of 1% agar and added as the top layer. Cells were fed with media and 1% agar at a 2:1 ratio.
